Plain-English translation of NCT06655376 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing whether patients with a HeartMate 3 left ventricular assist device (a mechanical heart pump) can safely stop taking while continuing (a blood thinner). Currently, these patients take both medications together to prevent dangerous blood clots. Researchers want to know if removing reduces serious bleeding without increasing the risk of clots or strokes.
Patients with mechanical heart pumps face a difficult balance: they need blood thinners to prevent life-threatening clots, but the medication combination they currently take can cause serious, sometimes life-threatening bleeding. This trial is looking for a safer approach that protects against clots while reducing bleeding complications.
You likely qualify if…
You likely don't qualify if…
If you join, you will be randomly assigned to take either alone or plus (the standard treatment). You will continue your assigned medication regimen for one year while doctors monitor you through regular visits and blood tests. Researchers will track whether you experience any bleeding events, blood clots, strokes, or other complications to see if the single-medication approach is as safe and effective as taking both drugs.
AI-generated summary from trial data · Jun 22, 2026 · Not medical advice
United States